Rabbit Polyclonal TGFβReceptorI(Ab-165) Antibody

The TGF-β Receptor I (Ab-165) antibody specifically targets Transforming Growth Factor Beta Receptor I (TGFBR1), also known as ALK5. a key component of the TGF-β signaling pathway. TGFBR1 is a serine/threonine kinase receptor that binds TGF-β ligands (e.g., TGF-β1. TGF-β2. TGF-β3) upon their association with TGF-β Receptor II (TGFBR2). This interaction triggers phosphorylation of TGFBR1. activating downstream Smad proteins (Smad2/3) to regulate gene expression involved in cell proliferation, differentiation, apoptosis, and immune responses. Dysregulation of TGF-β signaling is implicated in fibrosis, cancer progression, and autoimmune diseases. The Ab-165 epitope corresponds to a phosphorylated serine residue (Ser-165) within the kinase domain, making it a tool to detect activated TGFBR1 in signaling studies. This antibody is widely used in Western blotting, immunoprecipitation, and immunohistochemistry to investigate TGF-β pathway activation in cellular models, tissues, or disease contexts. Its specificity for the phosphorylated form allows researchers to distinguish active from inactive receptors, providing insights into TGF-β-mediated mechanisms in development, homeostasis, and pathology. Validation typically includes testing in TGF-β-stimulated systems, with applications in cancer biology, fibrosis research, and therapeutic development targeting TGF-β signaling.